Tubulointerstitial macrophage accumulation is regulated by sequentially expressed osteopontin and macrophage colony-stimulating factor: Implication for the role of atorvastatin

Mediators of Inflammation

Volumn 2006, Issue , 2006, Pages

  Tian, Shaojiang ^a   Ding, Guohua ^a   Jia, Ruhan ^a   Chu, Guili ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLONY STIMULATING FACTOR 1; OSTEOPONTIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FIBROSIS; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; URETER OBSTRUCTION; ANIMAL; BIOSYNTHESIS; BLOOD; CELL PROLIFERATION; GENE EXPRESSION REGULATION; INFLAMMATION; KIDNEY TUBULE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALIA;

ANIMALS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY TUBULES; LIPIDS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; OSTEOPONTIN; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33645555288     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/MI/2006/12919     Document Type: Article

References (28)

1. Eddy AA. Progression in chronic kidney disease. Advances in Chronic Kidney Disease. 2005;12(4):353-365.
2. Schwarz A, Mengel M, Gwinner W, et al. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney International. 2005;67(1):341-348.
3. Anders HJ, Belemezova E, Eis V, et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(1pr) mice. Journal of the American Society of Nephrology:JASN. 2004;15(6):1504-1513.
4. Wu Q, Jinde K, Endoh M, Sakai H. Clinical significance of costimulatory molecules CD80/CD86 expression in IgA nephropathy. Kidney International. 2004;65(3):888-896.
5. Young BA, Burdmann EA, Johnson RJ, et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney International. 1995;48(2):439-448.
6. Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC. Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney International. 1995;48(3):753-760.
7. Panzer U, Thaiss F, Zahner G, et al. Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. Kidney International. 2001;59(5):1762-1769.
8. Isbel NM, Hill PA, Foti R, et al. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney International. 2001;60(2):614-625.
9. Isbel NM, Nikolic-Paterson DJ, Hill PA, Dowling J, Atkins RC. Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis. Nephrology Dialysis Transplantation. 2001;16(8):1638-1647.
10. Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney International. 1999;56(2):571-580.
11. Le Meur Y, Tesch GH, Hill PA, et al. Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF/c-fms pathway. Journal of Leukocyte Biology. 2002;72(3):530-537.
12. Klahr S, Morrissey JJ. Obstructive nephropathy and renal fibrosis. American Journal of Physiology - Renal Physiology. 2002;283(5):F861-F875.
13. Massy ZA, Guijarro C. Statins: effects beyond cholesterol lowering. Nephrology Dialysis Transplantation. 2001;16(9):1738-1741.
14. Mizuguchi Y, Miyajima A, Kosaka T, Asano T, Asano T, Hayakawa M. Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. The Journal of Urology. 2004;172(6 pt 1):2456-2459.
15. Edgtton KL, Gow RM, Kelly DJ, Carmeliet P, Kitching AR. Plasmin is not protective in experimental renal interstitial fibrosis. Kidney International. 2004;66(1):68-76.
16. Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney International. 2001;59(4):1304-1314.
17. Isaka Y, Tsujie M, Ando Y, et al. Transforming growth factor-β1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney International. 2000;58(5):1885-1892.
18. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney International. 2001;60(5):1645-1657.
19. Persy VP, Verhulst A, Ysebaert DK, De Greef KE, De Broe ME. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney International. 2003;63(2):543-553.
20. Lenda DM, Kikawada E, Stanley ER, Kelley VR. Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation. The Journal of Immunology. 2003;170(6):3254-3262.
21. Lavaud S, Poirier B, Mandet C, et al. Inflammation is probably not a prerequisite for renal interstitial fibrosis in normoglycemic obese rats. American Journal of Physiology - Renal Physiology. 2001;280(4):F683-F694.
22. Lange-Sperandio B, Forbes MS, Thornhill B, Okusa MD, Linden J, Chevalier RL. A(2A) adenosine receptor agonist and PDE(4) inhibition delays inflammation but fails to reduce injury in experimental obstructive nephropathy. Nephron. Experimental Nephrology. 2005;100(3):e113-e123.
23. Vielhauer V, Berning E, Eis V, et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney International. 2004;66(6):2264-2278.
24. Vieira JM Jr, Mantovani E, Rodrigues LT, et al. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrology Dialysis Transplantation. 2005;20(8):1582-1591.
25. Serrano CV Jr, Yoshida VM, Venturinelli ML, et al. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis. 2001;157(2):505-512.
26. Park JK, Muller DN, Mervaala EM, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure-and cholesterol-lowering effects. Kidney International. 2000;58(4):1420-1430.
27. Wardle EN. Nuclear factor κB for the nephrologist. Nephrology Dialysis Transplantation. 2001;16(9):1764-1768.
28. Morrissey JJ, Klahr S. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. American Journal of Physiology - Renal Physiology. 1999;276(1 pt 2):F39-F45.